vs
AVANOS MEDICAL, INC.（AVNS）与Sanara MedTech Inc.（SMTI）财务数据对比。点击上方公司名可切换其他公司
AVANOS MEDICAL, INC.的季度营收约是Sanara MedTech Inc.的6.6倍（$180.9M vs $27.5M）。AVANOS MEDICAL, INC.净利率更高（-0.7% vs -5.9%，领先5.1%）。Sanara MedTech Inc.同比增速更快（4.6% vs 0.7%）。AVANOS MEDICAL, INC.自由现金流更多（$21.3M vs $3.9M）。过去两年Sanara MedTech Inc.的营收复合增速更高（21.8% vs 4.4%）
Avanos Medical是一家医疗科技企业，专注于研发生产临床医疗设备，核心业务围绕疼痛管理与慢性护理两大板块展开，致力于帮助患者加快康复、预防感染，同时减少临床治疗中阿片类药物的使用。
Sanara MedTech Inc.是一家总部位于美国的医疗科技企业，专注于研发、生产和销售外科手术、伤口护理、康复期护理类创新医疗产品，主要服务北美地区的医院、医疗机构及长期护理场所，旗下多款产品获FDA认证，旨在提升患者护理效果并降低医疗运营成本。
AVNS vs SMTI — 直观对比
营收规模更大
AVNS
是对方的6.6倍
$27.5M
营收增速更快
SMTI
高出3.9%
0.7%
净利率更高
AVNS
高出5.1%
-5.9%
自由现金流更多
AVNS
多$17.4M
$3.9M
两年增速更快
SMTI
近两年复合增速
4.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $180.9M | $27.5M |
| 净利润 | $-1.3M | $-1.6M |
| 毛利率 | 47.5% | 93.2% |
| 营业利润率 | 1.4% | 23.5% |
| 净利率 | -0.7% | -5.9% |
| 营收同比 | 0.7% | 4.6% |
| 净利润同比 | 99.7% | 5.3% |
| 每股收益（稀释后） | $-0.02 | $-0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVNSSMTI
| Q4 25 | $180.9M | $27.5M | ||
| Q3 25 | $177.8M | $26.3M | ||
| Q2 25 | $175.0M | $25.8M | ||
| Q1 25 | $167.5M | $23.4M | ||
| Q4 24 | $179.6M | $26.3M | ||
| Q3 24 | $170.4M | $21.7M | ||
| Q2 24 | $171.7M | $20.2M | ||
| Q1 24 | $166.1M | $18.5M |
净利润AVNSSMTI
| Q4 25 | $-1.3M | $-1.6M | ||
| Q3 25 | $-1.4M | $-30.4M | ||
| Q2 25 | $-76.8M | $-2.0M | ||
| Q1 25 | $6.6M | $-3.5M | ||
| Q4 24 | $-397.3M | $-1.7M | ||
| Q3 24 | $4.3M | $-2.9M | ||
| Q2 24 | $1.8M | $-3.5M | ||
| Q1 24 | $-900.0K | $-1.8M |
毛利率AVNSSMTI
| Q4 25 | 47.5% | 93.2% | ||
| Q3 25 | 48.4% | 92.9% | ||
| Q2 25 | 52.6% | 92.5% | ||
| Q1 25 | 53.6% | 92.2% | ||
| Q4 24 | 54.6% | 91.4% | ||
| Q3 24 | 54.5% | 90.8% | ||
| Q2 24 | 55.7% | 90.0% | ||
| Q1 24 | 57.1% | 89.8% |
营业利润率AVNSSMTI
| Q4 25 | 1.4% | 23.5% | ||
| Q3 25 | 0.1% | 11.2% | ||
| Q2 25 | -42.6% | -0.1% | ||
| Q1 25 | 6.1% | -8.9% | ||
| Q4 24 | -233.0% | 18.6% | ||
| Q3 24 | 7.0% | 3.6% | ||
| Q2 24 | 3.7% | -14.3% | ||
| Q1 24 | 2.4% | -8.3% |
净利率AVNSSMTI
| Q4 25 | -0.7% | -5.9% | ||
| Q3 25 | -0.8% | -115.5% | ||
| Q2 25 | -43.9% | -7.8% | ||
| Q1 25 | 3.9% | -15.1% | ||
| Q4 24 | -221.2% | -6.5% | ||
| Q3 24 | 2.5% | -13.2% | ||
| Q2 24 | 1.0% | -17.4% | ||
| Q1 24 | -0.5% | -9.5% |
每股收益（稀释后）AVNSSMTI
| Q4 25 | $-0.02 | $-0.32 | ||
| Q3 25 | $-0.03 | $-3.40 | ||
| Q2 25 | $-1.66 | $-0.23 | ||
| Q1 25 | $0.14 | $-0.41 | ||
| Q4 24 | $-8.64 | $-0.18 | ||
| Q3 24 | $0.09 | $-0.34 | ||
| Q2 24 | $0.04 | $-0.41 | ||
| Q1 24 | $-0.02 | $-0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $89.8M | $16.6M |
| 总债务越低越好 | $90.3M | $46.0M |
| 股东权益账面价值 | $778.2M | $5.9M |
| 总资产 | $1.1B | $72.9M |
| 负债/权益比越低杠杆越低 | 0.12× | 7.74× |
8季度趋势，按日历期对齐
现金及短期投资AVNSSMTI
| Q4 25 | $89.8M | $16.6M | ||
| Q3 25 | $70.5M | $14.9M | ||
| Q2 25 | $90.3M | $17.0M | ||
| Q1 25 | $97.0M | $20.7M | ||
| Q4 24 | $107.7M | $15.9M | ||
| Q3 24 | $89.0M | $16.3M | ||
| Q2 24 | $92.2M | $6.2M | ||
| Q1 24 | $75.8M | $2.8M |
总债务AVNSSMTI
| Q4 25 | $90.3M | $46.0M | ||
| Q3 25 | $93.4M | $45.1M | ||
| Q2 25 | $95.7M | $44.2M | ||
| Q1 25 | $98.0M | $43.4M | ||
| Q4 24 | $125.3M | $30.7M | ||
| Q3 24 | $152.6M | $30.1M | ||
| Q2 24 | $164.9M | $14.4M | ||
| Q1 24 | $167.2M | $9.7M |
股东权益AVNSSMTI
| Q4 25 | $778.2M | $5.9M | ||
| Q3 25 | $778.0M | $6.1M | ||
| Q2 25 | $776.3M | $35.4M | ||
| Q1 25 | $839.4M | $36.7M | ||
| Q4 24 | $828.5M | $39.4M | ||
| Q3 24 | $1.2B | $39.8M | ||
| Q2 24 | $1.2B | $41.7M | ||
| Q1 24 | $1.2B | $43.3M |
总资产AVNSSMTI
| Q4 25 | $1.1B | $72.9M | ||
| Q3 25 | $1.1B | $71.1M | ||
| Q2 25 | $1.0B | $98.8M | ||
| Q1 25 | $1.1B | $96.4M | ||
| Q4 24 | $1.2B | $88.1M | ||
| Q3 24 | $1.7B | $88.5M | ||
| Q2 24 | $1.7B | $73.4M | ||
| Q1 24 | $1.7B | $70.9M |
负债/权益比AVNSSMTI
| Q4 25 | 0.12× | 7.74× | ||
| Q3 25 | 0.12× | 7.33× | ||
| Q2 25 | 0.12× | 1.25× | ||
| Q1 25 | 0.12× | 1.18× | ||
| Q4 24 | 0.15× | 0.78× | ||
| Q3 24 | 0.12× | 0.76× | ||
| Q2 24 | 0.13× | 0.34× | ||
| Q1 24 | 0.14× | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.2M | $3.9M |
| 自由现金流经营现金流 - 资本支出 | $21.3M | $3.9M |
| 自由现金流率自由现金流/营收 | 11.8% | 14.0% |
| 资本支出强度资本支出/营收 | 3.8% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $43.1M | $2.2M |
8季度趋势，按日历期对齐
经营现金流AVNSSMTI
| Q4 25 | $28.2M | $3.9M | ||
| Q3 25 | $14.0M | $2.2M | ||
| Q2 25 | $6.8M | $2.7M | ||
| Q1 25 | $25.7M | $-2.0M | ||
| Q4 24 | $57.9M | $932.0K | ||
| Q3 24 | $23.0M | $2.1M | ||
| Q2 24 | $27.8M | $-1.4M | ||
| Q1 24 | $-8.0M | $-1.6M |
自由现金流AVNSSMTI
| Q4 25 | $21.3M | $3.9M | ||
| Q3 25 | $7.0M | $1.1M | ||
| Q2 25 | $-4.2M | $902.7K | ||
| Q1 25 | $19.0M | $-3.7M | ||
| Q4 24 | $53.1M | $859.9K | ||
| Q3 24 | $20.0M | $2.0M | ||
| Q2 24 | $21.9M | $-1.5M | ||
| Q1 24 | $-12.1M | $-1.7M |
自由现金流率AVNSSMTI
| Q4 25 | 11.8% | 14.0% | ||
| Q3 25 | 3.9% | 4.2% | ||
| Q2 25 | -2.4% | 3.5% | ||
| Q1 25 | 11.3% | -15.9% | ||
| Q4 24 | 29.6% | 3.3% | ||
| Q3 24 | 11.7% | 9.4% | ||
| Q2 24 | 12.8% | -7.3% | ||
| Q1 24 | -7.3% | -9.0% |
资本支出强度AVNSSMTI
| Q4 25 | 3.8% | 0.3% | ||
| Q3 25 | 3.9% | 4.0% | ||
| Q2 25 | 6.3% | 6.8% | ||
| Q1 25 | 4.0% | 7.4% | ||
| Q4 24 | 2.7% | 0.3% | ||
| Q3 24 | 1.8% | 0.0% | ||
| Q2 24 | 3.4% | 0.3% | ||
| Q1 24 | 2.5% | 0.4% |
现金转化率AVNSSMTI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | — | ||
| Q2 24 | 15.44× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
SMTI
| Soft Tissue Repair Products | $24.7M | 90% |
| Bone Fusion Products | $2.8M | 10% |
